SC TO-I

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE TO

(Rule 13e-4)

TENDER OFFER STATEMENT PURSUANT TO SECTION 14(D)(1) OR 13(E)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

Kennedy Lewis Capital Company

(Name of Subject Company (Issuer))

Kennedy Lewis Capital Company

(Names of Filing Person (Offeror and Issuer))

Common Shares of Beneficial Interest, Par Value $0.01 Per Share

(Title of Class of Securities)

N/A

(CUSIP Number of Class of Securities)

James Didden

Chairperson and President

Kennedy Lewis Capital Company

225 Liberty Street, Suite 4210

New York, NY 10281

(212) 782-3842

(Name, address and telephone no. of person authorized to receive notices and communications on behalf of filing person)

Copy to:

 

Richard Horowitz

Dechert LLP

1095 Avenue of the Americas

New York, NY 10036

(212) 698-3500

☐	Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the statement relates:
☐	Third-party tender offer subject to Rule 14d-1.
☒	Issuer tender offer subject to Rule 13e-4.
☐	Going-private transaction subject to Rule 13e-3.
☐	Amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing is a final amendment reporting the results of the tender offer:  ☐

The information contained in the offer to purchase and the related Letter of Transmittal (“Offer to Purchase” and the tender offer made thereby, the “Offer”), respectively, as each may be amended or supplemented from time to time, is hereby incorporated by reference in response to certain items of this Schedule TO.

Item 1.
Summary Term Sheet.

Reference is made to the Summary Term Sheet of the Offer to Purchase (as defined below) that is attached hereto as Exhibit (a)(1)(ii) and is hereby incorporated by reference.

Item 2.
Subject Company Information.

(a) The name of the issuer is Kennedy Lewis Capital Company (the “Company”). The Company is an externally managed, diversified closed-end management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the “1940 Act”). The Company is organized as a Delaware statutory trust. The principal executive office of the Company is located at 225 Liberty Street, Suite 4210, New York, NY 10281 and the Company’s telephone number is (212) 782-3842.

(b) As of the close of business on September 30, 2023, there were 10,769,456 shares of the Company’s common shares of beneficial interest, par value $0.01 per share (the “Common Shares”), outstanding. Subject to the conditions set forth in the Offer to Purchase, the Company will purchase up to 5.0% of the Company’s Common Shares outstanding as of September 30, 2023 (538,473 Common Shares) that are tendered by holders of the Company’s Common Shares (“Shareholders”) and not withdrawn as described in the Offer to Purchase (the “Offer Amount”).

(c) The Common Shares are not traded in any market.

Item 3.
Identity and Background of Filing Person.

(a) The Company is tendering for its own Common Shares. The information required by this Item is set forth in Item 2(a) above. Kennedy Lewis Capital Holdings LLC (the “Advisor”) serves as the investment adviser for the Company. The Advisor is located at 225 Liberty Street, Suite 4210, New York, NY 10281 and the Advisor’s telephone number is (212) 782-3842. The members of the Company’s Board of Trustees (the “Board”) are James Didden, Ankur Keswani, Doug Logigian, Julian Markby, and Catherine Smith (each, a “Trustee”). The Chairperson and President of the Company is James Didden; the Chief Financial Officer is Anthony Pasqua; the Controller is Gary Klayn; the Chief Compliance Officer is Gregory MacCordy; and the Vice President and Secretary is Rachel Presa. The Trustees and the executive officers of the Company may be reached at the Company’s business address and phone number set forth in Item 2(a) above.

(b)-(c) Not applicable.

Item 4.
Terms of the Transaction.

(a)(1)(i) Subject to the conditions set forth in the Offer to Purchase, the Company will purchase up to 5.0% of the Company’s Common Shares outstanding as of September 30, 2023 (538,473 Common Shares) that are tendered by Shareholders by 11:59 p.m., Eastern Time, on December 29, 2023 and not withdrawn as described in Item 4(a)(1)(v).

(ii) The purchase price of a Share (or portion thereof) tendered will be its net asset value as of December 31, 2023, or a later date determined by the Company if the Offer is extended (in each case, the “Valuation Date”), upon the terms and subject to the conditions set forth in the Offer to Purchase. Reference is made to the Cover Page, Section 2 “Offer to Purchase and Price” and Section 6 “Purchases and Payment” of the Offer to Purchase, which are incorporated herein by reference.

Each Shareholder that tenders Common Shares that are accepted for purchase will be sent a letter (the “Acceptance Letter”) notifying the Shareholder that the Company has received and accepted their tender. The Company will effect payment for such Common Shares in cash promptly after the determination of the net asset value per share as of the Valuation Date is finalized. The Form of the Acceptance Letter is attached hereto as Exhibit (a)(1)(iv) and incorporated herein by reference.

(iii) The Offer is scheduled to expire on December 29, 2023 unless extended. Reference is made to the Cover Page, Summary Term Sheet, Section 2 “Offer to Purchase and Price” and Section 5 “Withdrawal Rights” of the Offer to Purchase, which are incorporated herein by reference.

1

(iv) Not applicable.

(v) Reference is made to the Cover Page, Summary Term Sheet and Section 7 “Certain Conditions of the Offer” of the Offer to Purchase, which are incorporated herein by reference.

(vi) Reference is made to Section 5 “Withdrawal Rights” of the Offer to Purchase, which is incorporated herein by reference.

(vii) Reference is made to the Cover Page, Section 4 “Procedure for Tenders” and Section 5 “Withdrawal Rights” of the Offer to Purchase, which are incorporated herein by reference. All Shareholders tendering Common Shares should carefully review their Letter of Transmittal and follow the delivery instructions therein.

(viii) Reference is made to Section 4 “Procedure for Tenders” and Section 6 “Purchases and Payment” of the Offer to Purchase, which are incorporated herein by reference.

(ix) Reference is made to the Cover Page, Section 3 “Amount of Tender,” and Section 6 “Purchases and Payment” of the Offer to Purchase, which are incorporated herein by reference.

(x) Reference is made to Section 2 “Offer to Purchase and Price” of the Offer to Purchase, which is incorporated herein by reference.

(xi) Not applicable.

(xii) Reference is made to Section 10 “Certain Federal Income Tax Consequences” of the Offer to Purchase, which is incorporated herein by reference.

(a)(2) Not applicable.

(b) Any Common Shares to be purchased from any officer, Trustee or affiliate of the Company will be on the same terms and conditions as any other purchase of Common Shares. To the Company’s knowledge, none of the officers, Trustees, or affiliates (with the exception of any Shareholders of the Company who may be deemed to be affiliates solely due to their ownership of Common Shares) of the Company intends to tender Common Shares in the Offer.

Item 5.
Past Contracts, Transactions, Negotiations and Agreements With Respect to the Issuer’s Securities.

(a)-(d) Not applicable.

(e) The Board has the discretion to determine whether the Company will purchase Common Shares from Shareholders from time to time pursuant to written tenders. The Advisor expects that it will recommend to the Board that the Company offer to repurchase Common Shares from Shareholders quarterly. However, the Company is not required to conduct tender offers.

The Company does not know of any other contract, agreement, arrangement, or understanding, whether contingent or otherwise or whether or not legally enforceable, between the (i) Company, any of the Company’s executive officers or Trustees, any person controlling the Company, or any executive officer or director of any corporation ultimately in control of the Company and (ii) any other person with respect to any securities of the Company (including any contract, agreement, arrangement, or understanding concerning the transfer or the voting of any such securities, joint ventures, loan or option arrangements, puts or calls, guarantees of loans, guarantees against loss, or the giving or withholding of proxies, consents or authorizations).

Item 6.
Purposes of the Transaction and Plans or Proposals.

(a)-(b) Reference is made to Section 1 “Background and Purpose of the Offer” of the Offer to Purchase, which is incorporated herein by reference.

(c) Reference is made to Section 8 “Certain Information About the Company” of the Offer to Purchase, which is incorporated herein by reference. Because the Common Shares are not traded in any market, subsections (6), (7), and (8) of Regulation M-A Item 1006(c) are not applicable to the Company.

2

Item 7.
Source and Amount of Funds or Other Consideration.

(a)-(b) Reference is made to Section 6 “Purchases and Payment” of the Offer to Purchase, which is incorporated herein by reference.

(c) Not applicable.

(d) None of the Company, the Advisor or the Board or any person controlling the Company, the Advisor or the Board has determined at this time to borrow funds to purchase Common Shares tendered in connection with the Offer. Depending on the dollar amount of Common Shares tendered and prevailing general economic and market conditions, the Company, in its sole discretion, may decide to seek to borrow money to fund all or a portion of the purchase amount for Common Shares, subject to compliance with applicable law. The Company expects that the repayment of any amounts borrowed will be financed from additional funds contributed to the Company by existing or new Shareholders.

Item 8.
Interest in Securities of the Subject Company.

(a) Based on the number of Common Shares outstanding as of September 30, 2023, the following persons own the number of Common Shares indicated in the below table.

Person	Common Shares	Percentage of the Company’s Outstanding Common Shares
Kennedy Lewis Management LP	40,100	*
Advisor	517	*
James Didden	62,877	*
Doug Logigian	—	—
Ankur Keswani	—	—
Julian Markby	—	—
Catherine Smith	—	—
Gary Klayn	—	—
Gregory MacCordy	—	—
Anthony Pasqua	—	—
Rachel Presa	—	—

*
Less than 1%.

None of the persons listed above intends to tender any of his or her Common Shares in the Offer. Addresses for each of the persons listed above are provided in Item 3.

(b) Reference is made to Section 8 “Certain Information About the Company” of the Offer to Purchase, which is incorporated herein by reference. During the past sixty (60) days, the Company has not issued any Common Shares to the Advisor, Trustees and officers of the Company. Except as previously disclosed in the Company’s filings with the Securities and Exchange Commission in connection with the Company’s private continuous offering of Common Shares, there have been no other transactions in Common Shares effected during the past sixty (60) days by the Company, the Advisor, or any Trustee or executive officer of the Company, or any person controlling the Company or the Advisor.

Item 9.
Persons/Assets Retained, Employed, Compensated or Used.

(a) No persons have been employed, retained, or are to be compensated by the Company to make solicitations or recommendations in connection with the Offer to Purchase.

Item 10.
Financial Statements.

(a) Not applicable. The consideration offered to security holders consists solely of cash. The Offer is not subject to any financing condition, and Kennedy Lewis Capital Company is a public reporting company under Section 13(a) of the Exchange Act that files reports electronically on EDGAR.

(b) Not applicable.

3

Item 11.
Additional Information.

(a) (1) None.

(2) None.

(3) Not applicable.

(4) None.

(5) None.

(c) The Offer to Purchase, attached hereto as Exhibit (a)(1)(ii), is incorporated herein by reference in its entirety.

Item 12a.
Exhibits.

(a)(1)(i) Cover Letter to Offer to Purchase and Letter of Transmittal.

(ii) Offer to Purchase.

(iii) Form of Letter of Transmittal.

(iv) Form of Letter from the Company to Shareholders in Connection with the Company’s Acceptance of Common Shares.

(v) Forms of Notice of Withdrawal of Tender.

(a)(2)-(4) Not applicable.

(b) Not applicable.

(d) Not applicable.

(g) Not applicable.

(h) Not applicable.

Item 12b.
Filing Fees.

Filing Fee Table.

Item 13.
Information Required By Schedule 13e-3.

Not applicable.

4

EXHIBIT INDEX

Exhibit
(a)(1)(i)	Cover Letter to Offer to Purchase and Letter of Transmittal.
(a)(1)(ii)	Offer to Purchase.
(a)(1)(iii)	Form of Letter of Transmittal.
(a)(1)(iv)	Form of Letter from the Company to Shareholders in Connection with the Company’s Acceptance of Common Shares.
(a)(1)(v)	Forms of Notice of Withdrawal of Tender.
(b)	Calculation of Filing Fees Table.

5

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	KENNEDY LEWIS CAPITAL COMPANY
	By:	/s/ Anthony Pasqua
	Name:	Anthony Pasqua
	Title:	Chief Financial Officer
Dated: November 30, 2023

6

EX-99.(A)(1)(I)

Exhibit (a)(1)(i)

KENNEDY LEWIS CAPITAL COMPANY

c/o Kennedy Lewis Capital Holdings LLC

225 Liberty Street, Suite 4210

New York, NY 10281

 

If you do not want to sell your common shares of

beneficial interest at this time, please disregard this notice.

This is simply a notification of the Company’s repurchase offer.

November 30, 2023

Dear Shareholder:

This letter serves to inform you of important dates relating to a repurchase offer by Kennedy Lewis Capital Company (the “Company”). If you are not interested in tendering your common shares of beneficial interest in the Company (“Common Shares”) for repurchase at this time, please disregard this notice and take no action.

Please note that the sale of Common Shares may be subject to income and transfer taxes.

The tender offer period will begin on November 30, 2023 and end at 11:59 p.m., Eastern Time, on December 29, 2023. The purpose of the tender offer is to provide liquidity to shareholders of the Company. Common Shares may be presented to the Company for repurchase only by tendering them during the tender offer period.

If you do not wish to sell your Common Shares for any reason, simply disregard this notice. No action is required if you do not wish to sell any portion of your Common Shares at this time.

Should you wish to tender all or a portion of your Common Shares during this tender offer period, please complete the enclosed Letter of Transmittal and return it by mail or email to the Company’s Transfer Agent, SS&C GIDS, Inc., Attention: Kennedy Lewis Capital Company, using one of the below options as instructed in the Letter of Transmittal:

Mail:	PO Box 219213
	Kansas City, MO 64121-9213
Email:	kennedyai@dstsystems.com

If you hold Common Shares registered in the name of a broker, dealer, commercial bank, trust company or other nominee, you must contact that institution in order to tender your Common Shares.

All Shareholders tendering Common Shares should carefully review their Letter of Transmittal and follow the delivery instructions therein. The method of delivery of the Letter of Transmittal and all other required documents is at the election and sole risk of the tendering Shareholder.

All tenders of Common Shares must be received in good order by the Company’s Transfer Agent by 11:59 p.m., Eastern Time, on December 29, 2023.

If you have any questions, please refer to the attached Offer to Purchase, which contains additional important information about the repurchase offer, or call (866) 966-0157.

Sincerely,

Kennedy Lewis Capital Company

EX-99.(A)(1)(II)

Exhibit (a)(1)(ii)

KENNEDY LEWIS CAPITAL COMPANY

c/o Kennedy Lewis Capital Holdings LLC

225 Liberty Street, Suite 4210

New York, NY 10281

 

Offer to Purchase Up to 538,473

Common Shares of Beneficial Interest

Dated November 30, 2023

 

The Offer and Withdrawal Rights Will Expire at

11:59 p.m., Eastern Time, on December 29, 2023,

Unless the Offer is Extended

To the Shareholders of Kennedy Lewis Capital Company:

Subject to the terms and conditions set forth in this offer to purchase (“Offer to Purchase”) and the related Letter of Transmittal (which together with this Offer to Purchase constitutes the “Offer”), Kennedy Lewis Capital Company, an externally managed, diversified closed-end management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the “1940 Act”), and is organized as a Delaware statutory trust (the “Company”), is offering to purchase up to 5.0% of its common shares of beneficial interest, par value $0.01 per share (the “Common Shares”), outstanding as of September 30, 2023 (538,473 Common Shares), pursuant to tenders by shareholders of the Company (“Shareholders”) at a price equal to the net asset value per Share as of December 31, 2023 or a later date determined by the Company if the Offer is extended (the “Valuation Date”). This Offer is currently scheduled to expire at 11:59 p.m., Eastern Time, on December 29, 2023 (the “Expiration Date”), but the Company may extend this date; if it does, the Valuation Date may be changed. This Offer is being made to all Shareholders of the Company and is not conditioned on any minimum amount of Common Shares being tendered, but is subject to certain conditions described below. The Common Shares are not traded on any established trading market.

Shareholders should realize that the value of the Common Shares tendered in this Offer will likely change between the most recent time net asset value was calculated and communicated to them and the Valuation Date (the relevant date for determining the value of the Common Shares tendered to the Company for purposes of calculating the purchase price of such Common Shares) and such change could be material. The net asset value per Common Share as of September 30, 2023 was $20.39. The most recently calculated net asset value for the Common Shares was $20.45 per Share as of October 31, 2023.

Shareholders desiring to tender all or any portion of their Common Shares in accordance with the terms of the Offer should complete and sign the attached Letter of Transmittal and mail or email it to the Company’s transfer agent, SS&C GIDS, Inc. (the “Transfer Agent”), in the manner provided for in the Letter of Transmittal and set forth in Section 4 “Procedure for Tenders” below or request that your broker, dealer, commercial bank, trust company or other nominee effect the tender for you. If you hold Common Shares registered in the name of a broker, dealer, commercial bank, trust company or other nominee, you must contact that institution in order to tender your Common Shares.

IMPORTANT

The Company makes no recommendation to any Shareholder as to whether to tender or refrain from tendering Common Shares. Shareholders must make their own decisions whether to tender Common Shares and, if so, the portion of their Common Shares to tender.

Because each Shareholder’s investment decision is a personal one, based on its financial circumstances, no person has been authorized to make any recommendation on behalf of the Company as to whether Shareholders should tender Common Shares pursuant to the Offer. No person has been authorized to give any information or to make any representations in connection with the Offer other than those contained herein or in the Letter of Transmittal. If given or made, such recommendation and such information and representations must not be relied on as having been authorized by the Company.

This transaction has not been approved or disapproved by the Securities and Exchange Commission the (“SEC”) or the Commodity Futures Trading Commission (the “CFTC”) nor has the SEC, the CFTC, or any

state securities commission passed on the fairness or merits of such transaction or on the accuracy or adequacy of the information contained in this document. Any representation to the contrary is unlawful.

The Offer is not being made to (nor will tenders be accepted from or on behalf of) holders of Common Shares in any jurisdiction in which the making of the Offer or the acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdictions. The Company is not aware of any jurisdiction in which the Offer or tenders pursuant thereto would not be in compliance with the laws of such jurisdiction. However, the Company reserves the right to exclude Shareholders from the Offer in any jurisdiction in which it is asserted that the Offer cannot lawfully be made. The Company believes such exclusion is permissible under applicable laws and regulations, provided the Company makes a good faith effort to comply with any state law deemed applicable to the Offer.

Questions and requests for assistance and requests for additional copies of the Offer may be directed to the Transfer Agent:

SS&C GIDS, Inc.

 Attention: Kennedy Lewis Capital Company

PO Box 219213

Kansas City, MO 64121-9213

Tel: (866) 966-0157

Email: kennedyai@dstsystems.com

TABLE OF CONTENTS

Summary Term Sheet		1
1.	Background and Purpose of the Offer	2
2.	Offer to Purchase and Price	2
3.	Amount of Tender	2
4.	Procedure for Tenders	3
5.	Withdrawal Rights	4
6.	Purchases and Payment	4
7.	Certain Conditions of the Offer	5
8.	Certain Information About the Company	5
9.	Full Tender by DRIP Participants	6
10.	Certain Federal Income Tax Consequences	6
11.	Miscellaneous	9

SUMMARY TERM SHEET

This is a summary of the features of the Offer. To understand the Offer fully and for a more complete discussion of the terms and conditions of the Offer, you should read carefully this entire Offer to Purchase and the related Letter of Transmittal.

• As disclosed in the Company’s public filings made with the Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company may from time to time offer to repurchase a portion of its outstanding Common Shares pursuant to written tenders by Shareholders. Accordingly, the Company is offering to purchase up to 5.0% of the Company’s Common Shares outstanding as of September 30, 2023 (538,473 Common Shares) at a price equal to their net asset value (that is, the value of the Company’s total assets minus its total liabilities, divided by outstanding Common Shares) determined as of December 31, 2023 or such later date as may be determined by the Company if the Offer is extended (the “Valuation Date”). The Offer, which begins on November 30, 2023, will remain open until 11:59 p.m., Eastern Time, on December 29, 2023 (the “Expiration Date”). The Company reserves the right to adjust the Valuation Date to correspond to any extension of the Offer.

• Shareholders may tender all or a portion of their Common Shares.

• If a Shareholder tenders Common Shares and the Company purchases those Common Shares, the Company will effect payment for those Common Shares in cash promptly after the determination of the net asset value per share as of the Valuation Date is finalized.

• The Company does not expect to impose any charges on repurchases of Common Shares in the Company.

• If you tender only a portion of your Common Shares, you must maintain a minimum account balance of at least $10,000 as of the Valuation Date. The Company reserves the right to purchase all your Common Shares in the Company if you tender less than all of your Common Shares and the number of Common Shares you tender would cause your account in the Company to have a value lower than the required minimum balance. The Offer is being made to all Shareholders and is not conditioned on any minimum amount of Common Shares being tendered.

• If you are a participant in the Company’s dividend reinvestment plan (“DRIP”), in the event that you elect to tender your Common Shares in full, and such full tender is accepted by the Company, your participation in the DRIP will be automatically terminated as of the applicable Expiration Date, and any distributions due but not yet paid as of such date will be paid in cash on the scheduled dividend payment date.

• If the Company accepts the tender of any of your Common Shares, your proceeds will be funded from one or more of the following sources: cash on hand (including cash received from investments in the Company), borrowings and/or proceeds from the sale of portfolio holdings.

• Additional repurchases will be made at such times and on such terms as may be determined by the Board of Trustees of the Company (the “Board”). Kennedy Lewis Capital Holdings LLC, the Company’s investment adviser (the “Advisor”), expects that it will generally recommend to the Board that the Company offer to repurchase a portion of its outstanding Common Shares quarterly, but the Company is not required to make any such offer.

• Following this summary is a formal notice of the Offer, which remains open until the Expiration Date, unless extended. If you elect to tender your Common Shares, you have the right to change your mind and withdraw your tendered Common Shares at any time until the Expiration Date or, if such tendered Common Shares have not been accepted by the Company, at any time on or after January 30, 2023 (which is 40 business days after commencement of the Offer). If you would like to tender your Common Shares, you must complete the Letter of Transmittal enclosed with the Offer to Purchase, and return it as instructed in the Letter of Transmittal either (i) to the Transfer Agent, Attention: Kennedy Lewis Capital Company, by mail at PO Box 219213, Kansas City, MO 64121-9213, or via email at kennedyai@dstsystems.com; or (ii) request that your broker, dealer, commercial bank, trust company or other nominee effect the tender for you. If you choose to send the Letter of Transmittal via email, please mail the original promptly after you send it via email. Your properly completed mailed or

1

emailed Letter of Transmittal must be received prior to the Expiration Date. If you decide to tender, it is your responsibility to, and the Company strongly recommends that you do, confirm receipt of your Letter of Transmittal with the Transfer Agent by calling (866) 966-0157, Monday through Friday, except holidays, during normal business hours of 9:00 a.m. to 6:00 p.m. (Eastern Time). All Shareholders tendering Common Shares should carefully review their Letter of Transmittal and follow the delivery instructions therein.

• In all cases, payment for Common Shares tendered and accepted for payment pursuant to the Offer will be made only after timely receipt by the Transfer Agent, as specified in the Letter of Transmittal, of a properly completed and duly executed Letter of Transmittal and any other documents required by the Letter of Transmittal.

• The value of your Common Shares will likely change between the most recent time the net asset value was calculated and communicated to you and the Valuation Date (the date when the value of your investment will be determined for purposes of calculating the purchase price of your Common Shares).

• Please note that just as you have the right to withdraw your tender of Common Shares, the Company has the right to cancel, amend or postpone this offer at any time on or before the Expiration Date.

1. Background and Purpose of the Offer. The purpose of the Offer is to provide liquidity to Shareholders. Because there is no secondary trading market for the Common Shares, the Board has determined, after consideration of various matters, that the Offer is in the best interests of Shareholders in order to provide liquidity for Common Shares. The Board intends to consider the continued desirability of the Company making an offer to purchase Common Shares quarterly, but the Company is not required to make any such offer.

The purchase of Common Shares pursuant to the Offer will have the effect of increasing the proportionate interest in the Company of Shareholders who do not tender Common Shares. Shareholders who retain their Common Shares may be subject to increased risks that may possibly result from the reduction in the Company’s aggregate assets resulting from payment for the Common Shares tendered. These risks include the potential for greater volatility due to decreased diversification. A reduction in the aggregate assets of the Company may result in Shareholders who do not tender Common Shares bearing higher costs to the extent that certain expenses borne by the Company are relatively fixed and may not decrease if assets decline. These effects may be reduced or eliminated to the extent that additional purchases of Common Shares are made by new and existing investors from time to time, although there can be no assurances that such new or additional purchases will occur.

Common Shares that are tendered to the Company in connection with the Offer, if accepted for repurchase, will be repurchased, resulting in a change in the income ratio and an increase in the expense ratios of Common Shares owned by Shareholders remaining in the Company (assuming no further issuances of Common Shares).

2. Offer to Purchase and Price. The Company will purchase, upon the terms and subject to the conditions of the Offer, up to 5.0% of the Company’s Common Shares outstanding as of September 30, 2023 (538,473 Common Shares) that are properly tendered by, and not withdrawn (in accordance with Section 5 “Withdrawal Rights” below) before, the Expiration Date.

The Company reserves the right to extend, amend or cancel the Offer as described in Sections 3 and 7 below. The purchase price of a Common Share tendered will be its net asset value per Share as of the Valuation Date, payable as set forth in Section 6. The Company reserves the right to adjust the Valuation Date to correspond with any extension of the Offer.

As of the close of business on September 30, 2023, there were 10,769,456 Common Shares issued and outstanding, with a net asset value per Share of $20.39. The most recently calculated net asset value for the Common Shares was $20.45 per Share as of October 31, 2023. The value of the Common Shares tendered by Shareholders likely will change between the most recent time net asset value was calculated and communicated to you and the Valuation Date.

3. Amount of Tender. Subject to the limitations set forth below, Shareholders may tender all or a portion of their Common Shares. If you tender only a portion of your Common Shares, you must maintain a minimum account balance of at least $10,000 as of the Valuation Date. The Company reserves the right to purchase all

2

your Common Shares in the Company if you tender less than all of your Common Shares and the number of Common Shares you tender would cause your account in the Company to have a value lower than the required minimum balance. The Offer is being made to all Shareholders and is not conditioned on any minimum amount of Common Shares being tendered.

If less than 5.0% of the Company’s Common Shares outstanding as of September 30, 2023 (538,473 Common Shares) are properly tendered pursuant to the Offer and not withdrawn, the Company will, on the terms and subject to the conditions of the Offer, purchase all of the Common Shares so tendered unless the Company elects to cancel or amend the Offer, or postpone acceptance of tenders made pursuant to the Offer, as provided in Section 7 “Certain Conditions of the Offer” below. If more than 5.0% of the Company’s Common Shares outstanding as of September 30, 2023 (538,473 Common Shares) are duly tendered to the Company before the expiration of the Offer and not withdrawn, pursuant to Section 5 “Withdrawal Rights” below, the Company will accept Common Shares tendered on or before the Expiration Date for payment on a pro rata basis based on the number of tendered Common Shares; provided that the Company reserves the right in its sole discretion to purchase additional outstanding Common Shares representing up to 2.0% of the Company’s outstanding Common Shares without amending or extending the Offer as permitted by Rule 13e-4(f)(1) of the Exchange Act. The unaccepted portion of any tender of Common Shares made by a Shareholder pursuant to this Offer shall not be automatically carried forward or given priority in connection with any future tender offer made by the Company, but any Shareholder that wishes to have the Company repurchase Common Shares that were not accepted for repurchase in connection with this Offer may again tender those Common Shares in connection with, and subject to the terms and conditions of, any future tender offer made by the Company.

4. Procedure for Tenders.

Proper Tenders of Common Shares. You may tender your Common Shares in the Offer by delivering (by mail, delivery, or email) a properly completed and duly executed Letter of Transmittal (or an originally signed photocopy of the Letter of Transmittal), together with any other required documents, in accordance with the instructions included in the Letter of Transmittal. The completed and executed Letter of Transmittal must be received by the Transfer Agent, as specified in such Letter of Transmittal, prior to 11:59 p.m. Eastern Time, on the Expiration Date. All Shareholders tendering Common Shares should carefully review their Letter of Transmittal and follow the delivery instructions therein.

Method of Delivery. In all cases, payment for Common Shares tendered and accepted for payment pursuant to the Offer will be made only after timely receipt by the Transfer Agent of a properly completed and duly executed Letter of Transmittal (or an originally signed photocopy of the Letter of Transmittal), and any other documents required by the Letter of Transmittal.

If delivery is by mail, then registered mail with return receipt requested, properly insured, is recommended. If you choose delivery by email, please mail the original or an originally signed photocopy promptly after you email it. The method of delivery of any documents is at the election and complete risk of the Shareholder tendering Common Shares, including, but not limited to, the failure to receive any Letter of Transmittal or other document submitted via email.

In all cases, sufficient time should be allowed to ensure timely delivery. All questions as to the validity, form, eligibility (including time of receipt) and acceptance of tenders will be determined by the Company, in its sole discretion, and its determination shall be final and binding.

If you decide to tender, it is your responsibility to, and the Company strongly recommends that you do, confirm receipt of your Letter of Transmittal with the Transfer Agent by calling (866) 966-0157, Monday through Friday, except holidays, during normal business hours of 9:00 a.m. to 6:00 p.m. (Eastern Time).

The Company reserves the absolute right to reject any or all tenders (i) determined by it not to be in appropriate form or (ii) for which the acceptance of, or payment for, would, in the opinion of counsel for the Company, be unlawful. The Company also reserves the absolute right to waive any of the conditions of the Offer or any defect in any tender with respect to any particular Common Shares or any particular Shareholder (including, without limitation, the conditions relating to the dates on which Common Shares must be tendered or withdrawn), and the Company’s interpretation of the terms and conditions of the Offer will be final and binding. Unless waived, any defects or irregularities in connection with tenders must be cured within such time as the

3

Company shall determine. Tenders will not be deemed to have been made until the defects or irregularities have been cured or waived. None of the Company, the Board, the Advisor, or any of their agents is obligated to give notice of any defects or irregularities in tenders, nor shall any of them incur any liability for failure to give such notice.

IF YOU WANT TO TENDER ALL OR A PORTION OF YOUR COMMON SHARES, YOU MUST DELIVER THE LETTER OF TRANSMITTAL AND OTHER REQUIRED DOCUMENTS IN ACCORDANCE WITH THE INSTRUCTIONS IN THE LETTER OF TRANSMITTAL. ANY DOCUMENTS DELIVERED TO US OR ANY OTHER PERSON WILL NOT BE FORWARDED TO THE TRANSFER AGENT AND WILL NOT BE DEEMED TO BE PROPERLY TENDERED.

Return of Unpurchased Common Shares. If any tendered Common Shares are not purchased or are properly withdrawn prior to the Expiration Date, such Common Shares will be returned to the tendering Shareholder promptly after the expiration or termination of the Offer or the proper withdrawal of the Common Shares, without expense to the Shareholder.

5. Withdrawal Rights. Any Shareholder tendering Common Shares pursuant to this Offer may withdraw tendered Common Shares at any time before the Expiration Date or, if the Company has not accepted such tendered Common Shares, on or after January 30, 2023 (which is 40 business days from the date of commencement of the Offer). A form to use to give notice of withdrawal (the “Notice of Withdrawal”) is enclosed with the Offer to Purchase. To be effective, any notice of withdrawal must be timely received by the Transfer Agent as specified in the instructions to the Notice of Withdrawal. If you tendered your Common Shares through your broker, dealer, commercial bank, trust company or other nominee, you must instruct the broker, dealer, commercial bank, trust company or other nominee to arrange for the withdrawal of your Common Shares. All questions as to the form and validity (including time of receipt) of notices of withdrawal will be determined by the Company, in its sole discretion, and such determination shall be final and binding. Common Shares properly withdrawn shall not thereafter be deemed to be tendered for purposes of the Offer. However, withdrawn Common Shares may be re-tendered prior to the Expiration Date by following the procedures for tenders described above. Once the Company accepts your tendered Common Shares, upon expiration of the Offer, you will no longer be able to withdraw them other than as set forth above.

6. Purchases and Payment. For purposes of the Offer, the Company will be deemed to have accepted Common Shares that are tendered if and when it gives written notice to the tendering Shareholder of its election to purchase such Common Shares.

If a Shareholder tenders Common Shares and the Company purchases those Common Shares, the Company will effect payment for those Common Shares in cash promptly after the determination of the net asset value per share as of the Valuation Date is finalized.

In all cases, payment for any Common Shares tendered and accepted for payment pursuant to the Offer will be made only after timely receipt by the Transfer Agent, as specified in the instructions included in the Shareholder’s Letter of Transmittal, of (a) the Letter of Transmittal, properly completed and duly executed, and (b) any other documents required by the Letter of Transmittal. See Section 4 — “Procedure for Tenders.”

If any tendered Common Shares are not accepted for purchase for any reason pursuant to the terms and conditions of the Offer, such Common Shares will be returned or credited to the appropriate account, as applicable. Such unpurchased Common Shares will be returned or credited without expense to the tendering Shareholder promptly following expiration or termination of the Offer.

The Company does not expect to impose any charges on repurchases of Common Shares in the Company.

A Shareholder who tenders some but not all of such Shareholder’s Common Shares for repurchase will be required to maintain a minimum account balance of $10,000 in the Company based on the Valuation Date net asset value per Share. Such minimum account balance requirement may be waived by the Company, in its sole discretion. The Company reserves the right to reduce the number of Common Shares to be repurchased from a Shareholder so that the required account balance is maintained.

The Company expects that the purchase price for Common Shares acquired pursuant to the Offer to Purchase will be derived from cash on hand (including cash received from investments in the Company),

4

borrowings and/or proceeds from the sale of portfolio holdings. Payment for repurchased Common Shares may require the Company to liquidate portfolio holdings earlier than the Advisor would otherwise have caused these holdings to be liquidated, potentially resulting in losses, and may increase our investment-related expenses as a result of higher portfolio turnover rates.

7. Certain Conditions of the Offer. The Company reserves the right, at any time and from time to time, to extend the period of time during which the Offer is pending by notifying Shareholders of such extension. If the Company elects to extend the tender period, the Valuation Date may occur after December 31, 2023 and in that case, for purposes of determining the purchase price for tendered Common Shares, the net asset value of such Common Shares will be determined at a later date. During any such extension, all Common Shares previously tendered and not withdrawn will remain subject to the Offer. The Company also reserves the right, at any time and from time to time, up to and including acceptance of tenders pursuant to the Offer, to: (a) cancel the Offer and in the event of such cancellation, not to purchase or pay for any Common Shares tendered pursuant to the Offer; (b) amend the Offer; or (c) postpone the acceptance of Common Shares tendered. If the Company determines to amend the Offer or to postpone the acceptance of Common Shares tendered, it will, to the extent necessary, extend the period of time during which the Offer is open as provided above and will promptly notify Shareholders.

Please note that just as you have the opportunity to withdraw shares that you have tendered under certain circumstances, the Company has the right to cancel, amend or postpone the Offer at any time before accepting tendered Common Shares. The Company may cancel the Offer, amend the Offer or postpone the acceptance of tenders made pursuant to the Offer if: (a) the Company would not be able to liquidate portfolio securities in a manner that is orderly and consistent with the Company’s investment objectives and policies in order to purchase Common Shares tendered pursuant to the Offer; (b) there is, in the Board’s judgment, any (i) legal action or proceeding instituted or threatened challenging the Offer or that otherwise would have a material adverse effect on the Company, (ii) declaration of a banking moratorium by Federal or state authorities or any suspension of payment by banks in the United States or New York State that is material to the Company, (iii) limitation imposed by Federal or state authorities on the extension of credit by lending institutions, (iv) suspension of trading on any organized exchange or over-the-counter market where the Company has a material investment, (v) commencement of war, armed hostilities or other international or national calamity directly or indirectly involving the United States that is material to the Company, (vi) material decrease in the net asset value of the Company from the net asset value of the Company as of the commencement of the Offer, or (vii) other event or condition that would have a material adverse effect on the Company or its Shareholders if Common Shares tendered pursuant to the Offer were purchased; or (c) the Independent Trustees (as defined in Section 2(a)(19) of the 1940 Act) of the Company determine that it is not in the best interest of the Company to purchase Common Shares pursuant to the Offer. However, there can be no assurance that the Company will exercise its right to extend, amend or cancel the Offer or to postpone acceptance of tenders pursuant to the Offer.

8. Certain Information About the Company. The Company is an externally managed, diversified closed-end management investment company that has elected to be regulated as a business development company under the 1940 Act and is organized as a Delaware statutory trust. The principal executive office of the Company is located at 225 Liberty Street, Suite 4210, New York, NY 10281 and the Company’s telephone number is (212) 782-3842. The Common Shares are not traded on any established trading market.

The Company does not have any plans or proposals that relate to or would result in: (a) the acquisition by any person of additional Common Shares or the disposition of Common Shares; (b) an extraordinary transaction, such as a merger, reorganization or liquidation, involving the Company; (c) any material change in the present distribution policy or indebtedness or capitalization of the Company (other than pursuant to borrowing arrangements made in the ordinary course of business); (d) any change in the identity of the investment adviser or Trustees of the Company, or in the management of the Company including, but not limited to, any plans or proposals to change the number or the term of the Trustees, to change any material term of the investment advisory arrangements with the Advisor; (e) a sale or transfer of a material amount of assets of the Company (other than as the Trustees determine may be necessary or appropriate to fund any portion of the purchase price for Common Shares acquired pursuant to this Offer to Purchase or in connection with the ordinary portfolio transactions of the Company); (f) any other material change in the Company’s structure or business; or (g) any changes in the Company’s organizational documents or other actions that may impede the acquisition of control of the Company by any person.

5

Based on the number of Common Shares outstanding as of September 30, 2023, the following persons (the named individuals being the Trustees and officers) own the number of Common Shares indicated in the below table:

Person	Common Shares	Percentage of the Company’s Outstanding Common Shares
Advisor	517	*
James Didden	62,877	*
Doug Logigian	—	—
Ankur Keswani	—	—
Julian Markby	—	—
Catherine Smith	—	—
Gary Klayn	—	—
Gregory MacCordy	—	—
Anthony Pasqua	—	—
Rachel Presa	—	—

*
Less than 1%.

Based on information available to the Company, none of the persons listed above intends to tender any of his or her Common Shares in the Offer.

During the past sixty (60) days, the Company has not issued any Common Shares to the Advisor, Trustees and officers of the Company. Except as previously disclosed in the Company’s filings with the SEC in connection with the Company’s private continuous offering of Common Shares, there have been no other transactions in Common Shares effected during the past sixty (60) days by the Company, the Advisor, or any Trustee or officer of the Company, or any person controlling the Company or the Advisor.

9. Full Tender by DRIP Participants. If you are a participant in the DRIP, in the event you elect to tender your Common Shares in full and such full tender is accepted by the Company, your participation in the DRIP will be automatically terminated as of the applicable Expiration Date and any distributions due but not yet paid as of such date will be paid in cash on the scheduled distribution payment date.

10. Certain Federal Income Tax Consequences. The following discussion is a general summary of the U.S. federal income tax consequences of the purchase of Common Shares by the Company from Shareholders pursuant to the Offer. This summary is based on U.S. federal income tax law as of the date hereof, including the Internal Revenue Code of 1986, as amended (the “Code”), applicable Treasury regulations, Internal Revenue Service (“IRS”) rulings, judicial authority and current administrative rulings and practice, all of which are subject to change, possibly with retroactive effect. There can be no assurance that the IRS would not assert, or that a court would not sustain, a position contrary to any of those set forth below, and the Company has not obtained, nor does the Company intend to obtain, a ruling from the IRS or an opinion of counsel with respect to any of the consequences described below. Shareholders should also consult their own tax advisers regarding their particular situation and the potential tax consequences to them of a purchase of their Common Shares by the Company pursuant to the Offer, including potential state, local and foreign taxation, as well as any applicable transfer taxes.

Except where noted, this discussion deals only with Common Shares held as capital assets and does not deal with all tax consequences that may be relevant to Shareholders in light of their particular circumstances or to Shareholders subject to special tax rules (including, without limitation, partnerships or other pass-through entities (and investors therein), dealers or traders in securities, financial institutions, tax-exempt organizations, insurance companies, U.S. expatriates, persons liable for the alternative minimum tax, persons holding Common Shares as a part of a hedging, conversion or constructive sale transaction or a straddle, nonresident alien individuals present in the United States for more than 182 days during the taxable year in which their Common Shares are repurchased pursuant to the Offer or U.S. Shareholders (as defined below) whose functional currency is not the

6

U.S. dollar). In addition, this discussion does not address any considerations in respect of any withholding required pursuant to the Foreign Account Tax Compliance Act of 2010 (including the Treasury regulations promulgated thereunder and intergovernmental agreements entered into in connection therewith).

As used herein, the term “U.S. Shareholder” refers to a Shareholder who is (i) an individual citizen or resident of the United States, (ii) a corporation created or organized in or under the laws of the United States or any State thereof or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless of the source of such income, or (iv) a trust if (a) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons (as defined in the Code) have the authority to control all substantial decisions of the trust or (b) the trust has a valid election in effect under applicable Treasury regulations to be treated as a U.S. person. The term “Non-U.S. Shareholder” refers to a Shareholder who is an individual, corporation, estate or trust and is not a U.S. Shareholder. Except for the discussion under “Non-U.S. Shareholders” and “Backup Withholding,” the following discussion is limited to U.S. Shareholders.

Sale or Exchange of Common Shares. Under Section 302(b) of the Code, a Shareholder (other than a tax-exempt Shareholder) whose Common Shares are repurchased pursuant to the Offer generally will be treated as having sold the Common Shares and will recognize gain or loss for U.S. federal income tax purposes, so long as either (a) such Shareholder tenders, and the Company repurchases, all of such Shareholder’s Common Shares (i.e., reduces such Shareholder’s percentage ownership of the Company to 0%), (b) such Shareholder meets numerical safe harbors with respect to percentage voting interest and reduction in ownership of the Company following the completion of the Offer for the distribution to be “substantially disproportionate” with respect to such Shareholder, or (c) the tender otherwise results in a distribution that is “not essentially equivalent to a dividend,” which determination depends on a Shareholder’s particular facts and circumstances, including the initial size of and extent to which a Shareholder’s ownership percentage interest in the Company is reduced. For these purposes, a shareholder’s ownership of the Company is determined after applying the ownership attribution rules under Section 318 of the Code. The gain or loss recognized by a Shareholder in such case generally will equal the difference between the price paid by the Company for the Common Shares pursuant to the Offer and the Shareholder’s adjusted tax basis in the Common Shares sold. A tendering Shareholder’s gain or loss will generally be capital gain or loss, and will generally be treated as long-term capital gain or loss if the Common Shares have been held for more than one year or as short-term capital gain or loss if the Common Shares have been held for one year or less. For these purposes, a Shareholder’s holding period in Common Shares repurchased pursuant to the Offer should terminate as of the Valuation Date. If a Shareholder realizes a gain upon the sale of its Common Shares and payment for the Common Shares is received after the close of the taxable year of the Shareholder in which the Valuation Date occurs, it is expected that, unless the Shareholder elects otherwise, the Shareholder will generally recognize such gain in the taxable year in which the proceeds are received. The maximum U.S. federal income tax rate applicable to short-term capital gains recognized by a non-corporate Shareholder is currently the same as the applicable ordinary income rate. In addition, the Code generally imposes a 3.8% Medicare contribution tax on the net investment income of certain individuals, estates and trusts to the extent their income exceeds certain threshold amounts. For these purposes, “net investment income” generally includes, among other things, (i) distributions paid by the Company of net investment income and capital gains, and (ii) any net gain from the sale, exchange or other taxable disposition of the Common Shares.

In the event that a tendering Shareholder’s ownership (taking into account deemed ownership under Section 318 of the Code) of Common Shares of the Company is not reduced to the extent required under the tests described above, such Shareholder would be deemed to receive a distribution from the Company under Section 301 of the Code with respect to the Common Shares held by the Shareholder after the tender (a “Section 301 distribution”). Such distribution, which would equal the price paid by the Company to such Shareholder for the Common Shares sold, would be taxable as a dividend to the extent of the Company’s current or accumulated earnings and profits allocable to such distribution, with the excess treated as a return of capital reducing the Shareholder’s tax basis in the Common Shares, and thereafter as capital gain. If any amounts received by a Shareholder are treated as a dividend, the tax basis (after any adjustment for a return of capital) in the Common Shares sold pursuant to the Offer will generally be transferred to any remaining Common Shares held by the Shareholder. It is not expected that any amount treated as a dividend will be eligible for the dividends received deduction allowed to corporations or for the reduced U.S. federal income tax rates that are currently imposed on certain “qualified dividend income” received by non-corporate Shareholders.

Provided that no tendering Shareholder is treated as receiving a Section 301 distribution as a result of the Offer, Shareholders whose percentage ownership of the Company increases as a result of the Offer will not be

7

treated as realizing constructive distributions by virtue of that increase. In the event that any tendering Shareholder is deemed to receive a Section 301 distribution as a result of the Offer, it is possible that Shareholders whose percentage ownership of the Company increases as a result of the Offer, including Shareholders who do not tender any Common Shares pursuant to the Offer, will be deemed to receive a constructive distribution under Section 305(c) of the Code in an amount determined by the increase in their percentage ownership of the Company as a result of the Offer. Such constructive distribution will be treated as a dividend to the extent of the Company’s current or accumulated earnings and profits allocable to it.

Under the “wash sale” rules under the Code, provided the tender of Common Shares pursuant to the Offer is treated as a sale or exchange (and not a distribution as described above), loss recognized on Common Shares sold pursuant to the Offer will ordinarily be disallowed to the extent the Shareholder acquires other Common Shares of the Company (whether through automatic reinvestment of dividends or otherwise) or substantially identical stock or securities within 30 days before or after the date the tendered Common Shares are purchased pursuant to the Offer. In that event, the basis and holding period of the Common Shares (or substantially identical stock or securities) acquired will be adjusted to reflect the disallowed loss. Any loss realized by a Shareholder on the sale of Common Shares held by the Shareholder for six months or less will be treated for U.S. federal income tax purposes as a long-term capital loss to the extent of any distributions or deemed distributions of long-term capital gains received by the Shareholder with respect to such Common Shares. A Shareholder’s ability to utilize capital losses may be limited under the Code.

Non-U.S. Shareholders. Generally, if a Non-U.S. Shareholder’s sale of Common Shares pursuant to the Offer is respected as a sale or exchange for U.S. federal income tax purposes pursuant to Section 302(b) of the Code (as discussed above), any gain realized by the Non-U.S. Shareholder will not be subject to U.S. federal income tax or to any U.S. tax withholding, provided that such gain is not effectively connected with a trade or business carried on in the United States by the Non-U.S. Shareholder. If, however, all or a portion of the proceeds received by a tendering Non-U.S. Shareholder is treated for U.S. federal income tax purposes as a distribution by the Company that is a dividend, or if a Non-U.S. Shareholder is otherwise treated as receiving a deemed distribution that is a dividend by reason of the Shareholder’s increase in its percentage ownership of the Company resulting from other Shareholders’ sale of Common Shares pursuant to the Offer, and absent a statutory exemption, the dividend received or deemed received by the Non-U.S. Shareholder will be subject to a U.S. withholding tax of 30% (or a lower treaty rate, if applicable). If any gain or dividend income realized in connection with the tender of Common Shares by a Non-U.S. Shareholder is effectively connected with a trade or business carried on in the United States by the Non-U.S. Shareholder, such gain or dividend will generally be taxed at the regular rates applicable to U.S. Shareholders. In addition, if the Non-U.S. Shareholder is a non-U.S. corporation, it may be subject to a branch profits tax of 30% (or a lower treaty rate) on its effectively connected income. In order to qualify for an exemption from withholding for effectively connected income or for lower withholding tax rates under income tax treaties, or to establish an exemption from backup withholding, a Non-U.S. Shareholder must comply with special certification and filing requirements relating to its non-U.S. status (including, in general, furnishing an IRS Form W-8ECI, W-8BEN, W-8BEN-E, or W-8IMY, as applicable, or any substitute form). Because an applicable withholding agent may not be able to determine if a particular Non-U.S. Shareholder qualifies for sale or exchange treatment pursuant to Section 302(b) of the Code, such agent may withhold U.S. federal income tax equal to 30% of the gross payments payable to a Non-U.S. Shareholder unless the agent determines that an exemption or a reduced rate of withholding is available as discussed above. However, a Non-U.S. Shareholder may be eligible to obtain a refund of all or a portion of any tax withheld if such Non-U.S. Shareholder establishes that it qualifies for sale or exchange treatment pursuant to Section 302(b) of the Code or is otherwise able to establish that no tax or a reduced amount of tax is due. See the section of the Company’s Confidential Private Placement Memorandum, as amended or supplemented, entitled “Certain U.S. Federal Income Tax Considerations—Non-U.S. Holders” for further information concerning the taxation of Non-U.S. Shareholders, which the Company will provide to eligible Shareholders upon request. Non-U.S. Shareholders are urged to consult their tax advisors regarding the application of U.S. federal income tax rules, including withholding, to their tender of Common Shares.

FATCA. Sections 1471-1474 of the Code, and the U.S. Treasury Regulations and IRS guidance issued thereunder (collectively, “FATCA”), generally require the Company to obtain information sufficient to identify the status of each of its shareholders under FATCA or under an applicable intergovernmental agreement (an “IGA”). If a shareholder fails to provide this information or otherwise fails to comply with FATCA or an IGA, the Company or its agent may be required to withhold under FATCA 30% of ordinary dividends the

8

Company pays (or is deemed to pay) to that shareholder. The IRS and the Department of Treasury have issued proposed regulations providing that gross proceeds the Company pays to a shareholder for a share repurchase treated as a sale or exchange will not be subject to FATCA withholding. If an amount paid (or deemed paid) by the Company is subject to FATCA withholding, the Company or its agent is required to withhold even if the payment would otherwise be exempt from withholding under rules applicable to foreign shareholders. Foreign shareholders are urged to consult their tax adviser regarding the applicability of FATCA.

Backup Withholding. The Company generally is required to withhold and remit to the U.S. Treasury a percentage of the taxable distributions and redemption proceeds paid to any U.S. Shareholder who fails to properly furnish the Company with a correct taxpayer identification number and a certification that such Shareholder is not subject to backup withholding (generally, through the provision of a properly executed IRS Form W-9). A Non-U.S. Shareholder generally can establish an exemption from backup withholding by certifying as to its foreign status (generally, through the provision of a properly executed IRS Form W-8BEN, W-8BEN-E or other applicable Form W-8).

Shareholders should provide the Company with a completed IRS Form W-9, W-8BEN or W-8BEN-E, as applicable, or other appropriate form in order to avoid backup withholding on the payment they receive from the Company regardless of how they are taxed with respect to their tendered Common Shares. Backup withholding is not an additional tax and any amount withheld may be credited against a Shareholder’s U.S. federal income tax liability, and may entitle the Shareholder to a refund, provided in each case that the appropriate information is furnished to the IRS.

Other Tax Consequences. The Company’s purchase of Common Shares in the Offer may directly result in, or contribute to a subsequent, limitation on the Company’s ability to use capital loss carryforwards to offset future gains. Therefore, in certain circumstances, Shareholders who remain Shareholders following completion of the Offer may pay taxes sooner, or pay more taxes, than they would have had the Offer not occurred.

Payments for repurchased Common Shares may require the Company to liquidate all or a portion of its portfolio holdings. Such action could give rise to increased taxable distributions to Shareholders, including distributions of ordinary income or short-term capital gains taxable to individuals as ordinary income.

Under Treasury regulations directed at tax shelter activity, if a Shareholder recognizes a loss of $2 million or more for an individual Shareholder or $10 million or more for a corporate Shareholder, such Shareholder must file with the IRS a disclosure statement on Form 8886. Direct holders of portfolio securities are in many cases excepted from this reporting requirement, but under current guidance, shareholders of a regulated investment company (“RIC”), such as the Company, are not excepted. Future guidance may extend the current exception from this reporting requirement to shareholders of most or all RICs. The fact that a loss is reportable under these regulations does not affect the legal determination of whether the taxpayer’s treatment of the loss is proper. Shareholders should consult their own tax advisers concerning any possible disclosure obligation with respect to their disposition of Common Shares pursuant to the Offer.

11. Miscellaneous. The Offer is not being made to, nor will tenders be accepted from, Shareholders in any jurisdiction in which the Offer or its acceptance would not comply with the securities or Blue Sky laws of such jurisdiction. The Company is not aware of any jurisdiction in which the Offer or tenders pursuant thereto would not be in compliance with the laws of such jurisdiction. However, the Company reserves the right to exclude Shareholders from the Offer in any jurisdiction in which it is asserted that the Offer cannot lawfully be made. The Company believes such exclusion is permissible under applicable laws and regulations, provided the Company makes a good faith effort to comply with any state law deemed applicable to the Offer.

The Company has filed an Issuer Tender Offer Statement on Schedule TO with the SEC, which includes certain information relating to the Offer summarized herein. A free copy of such statement may be obtained from the Company upon request at 225 Liberty Street, Suite 4210, New York, NY 10281 or by phone at (212) 782-3842, by contacting the Transfer Agent at (866) 966-0157, or from the SEC’s internet web site, http://www.sec.gov.

Financial Statements

The consideration offered to security holders consists solely of cash. The Offer is not subject to any financing condition, and Kennedy Lewis Capital Company is a public reporting company under Section 13(a) of the Exchange Act that files reports electronically on EDGAR.

9

EX-99.(A)(1)(III)

Exhibit (a)(1)(iii)

Letter of Transmittal

Regarding Common Shares in Kennedy Lewis Capital Company

Tendered Pursuant to the Offer to Purchase

Dated November 30, 2023

The Offer and withdrawal rights will expire on December 29, 2023

and this Letter of Transmittal must be received by

the Company’s Transfer Agent, either by mail or by email, by 11:59 p.m.,

Eastern Time, on December 29, 2023, unless the Offer is extended

 

Complete this Letter of Transmittal and follow the Transmittal

Instructions included herein

NOTE: SIGNATURES MUST BE PROVIDED BELOW. PLEASE READ THIS LETTER OF TRANSMITTAL CAREFULLY.

Ladies and Gentlemen:

The undersigned hereby tenders to Kennedy Lewis Capital Company, an externally managed, diversified closed-end investment management company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the “1940 Act”) and is organized as a Delaware statutory trust (the “Company”), the common shares of beneficial interest, par value $0.01 per share (the “Common Shares”), or a portion thereof held by the undersigned, described and specified below, on the terms and conditions set forth in the Offer to Purchase dated November 30, 2023 (the “Offer to Purchase”), receipt of which is hereby acknowledged, and in this Letter of Transmittal (which together with the Offer to Purchase constitute the “Offer”). The Offer and this Letter of Transmittal are subject to all the terms and conditions set forth in the Offer to Purchase, including, but not limited to, the absolute right of the Company to reject any and all tenders determined by it, in its sole discretion, not to be in the appropriate form.

IMPORTANT: If you hold Common Shares registered in the name of a broker, dealer, commercial bank, trust company or other nominee, you must contact that institution in order to tender your Common Shares and request that your broker, dealer, commercial bank, trust company or other nominee effect the tender for you.

The undersigned hereby sells to the Company the Common Shares or a portion thereof tendered hereby pursuant to the Offer.

The undersigned hereby warrants that the undersigned has full authority to sell the Common Shares or a portion thereof tendered hereby and that the Company will acquire good title thereto, free and clear of all liens, charges, encumbrances, conditional sales agreements or other obligations relating to the sale thereof, and not subject to any adverse claim, when and to the extent the same are purchased by it. Upon request, the undersigned will execute and deliver any additional documents necessary to complete the sale in accordance with the terms of the Offer.

The undersigned name(s) on this Letter of Transmittal must correspond exactly with the name(s) on the books and records of the Company maintained by SS&C GIDS, Inc., the Company’s transfer agent (the “Transfer Agent”). The undersigned recognizes that, under certain circumstances as set forth in the Offer to Purchase, the Company may amend, extend or terminate the Offer or may not be required to purchase any of the Common Shares tendered hereby. In any such event, the undersigned understands that the Common Shares not purchased, if any, will continue to be held by the undersigned and will not be tendered.

The undersigned understands that acceptance of Common Shares by the Company for payment will constitute a binding agreement between the undersigned and the Company upon the terms and subject to the conditions of the Offer. The undersigned understands that if the undersigned tenders Common Shares and the Company purchases those Common Shares, following the determination of the purchase price, cash payment of the purchase price for the Common Shares or a portion thereof of the undersigned, as described in Section 6 “Purchases and Payment” of the Offer to Purchase, will be made on behalf of the Company by check or wire transfer to the account identified by the undersigned below or, if no instructions are indicated, to the account on record with the Transfer Agent for the payment of dividends.

No alternative, conditional or contingent tenders will be accepted. All tendering shareholders, by execution of this Letter of Transmittal, waive any right to receive any notice of the acceptance of their Common Shares for payment.

All questions as to validity, form and eligibility (including time of receipt), including questions as to the proper completion or execution of any Letter of Transmittal or other required documents will be determined by the Company in its sole and absolute discretion (which may delegate power in whole or in part to the Transfer Agent) which determination will be final and binding. The Company reserves the absolute right to reject any or all tenders (i) determined by it not to be in appropriate form or (ii) for which the acceptance of, or payment for, would, in the opinion of counsel for the Company, be unlawful. The Company also reserves the absolute right to waive any defect or irregularity in the surrender of any Common Shares whether or not similar defects or irregularities are waived in the case of any other shareholder. A surrender will not be deemed to have been validly made until all defects and irregularities have been cured or waived. The Company and the Transfer Agent shall make reasonable efforts to notify any person of any defect in any Letter of Transmittal submitted to the Transfer Agent.

Backup Withholding. Under U.S. federal income tax laws, the Transfer Agent will be required to withhold a portion of the amount of any payments made to certain shareholders pursuant to the Offer. In order to avoid such backup withholding, each tendering shareholder or payee that is a United States person (for U.S. federal income tax purposes) who has not previously submitted to the Transfer Agent a correct, completed and signed Internal Revenue Service (“IRS”) Form W-9, should provide the Transfer Agent with such shareholder’s or payee’s correct taxpayer identification number (“TIN”) by completing a Form W-9 with the required certifications being made under penalties of perjury. A copy of such form may be obtained from the Transfer Agent or downloaded from the Internal Revenue Service’s website at the following address: https://www.irs.gov. If such shareholder is an individual, the TIN is such shareholder’s social security number. If the Transfer Agent is not provided with the correct TIN, the shareholder may be subject to penalties imposed by the IRS and payments that are made to such shareholder with respect to Common Shares purchased pursuant to the Offer may be subject to backup withholding. If backup withholding applies with respect to such non-exempt United States person, the Transfer Agent is required to withhold 24% of any payments of the purchase price made to the shareholder. Backup withholding is not an additional tax. Rather, the tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may be obtained from the IRS provided that the required information is furnished to the IRS in a timely manner.

In order to avoid backup withholding, a foreign shareholder who has not previously submitted to the Transfer Agent a correct, completed and signed version of the appropriate IRS tax form should submit to the Transfer Agent a properly completed applicable IRS Form W-8 (IRS Form W-8BEN for foreign individuals; or IRS Form W-8BEN-E for foreign corporations; or other applicable IRS forms), including certification of such shareholder’s foreign status, signed under penalties of perjury. Copies of such forms may be obtained from the Transfer Agent or downloaded from the Internal Revenue Service’s website at the following address: https://www.irs.gov.

Certain shareholders or payees (including, among others, corporations, non-resident foreign individuals and foreign entities) are not subject to these backup withholding and reporting requirements, but should certify their exemption by completing the applicable Form W-9 or W-8 if they have not previously submitted to the Transfer Agent a correct, completed and signed version of the appropriate IRS tax form, or if their applicable Form W-8 is no longer current. Failure to complete the applicable Form W-9 or W-8 will not, by itself, cause Common Shares to be deemed invalidly tendered, but may require the Transfer Agent to withhold a portion of the amount of any payments made of the purchase price pursuant to the Offer.

NOTE: FAILURE TO COMPLETE AND RETURN THE APPLICABLE FORM W-9 OR FORM W-8 MAY RESULT IN BACKUP WITHHOLDING OF A PORTION OF ANY PAYMENTS MADE TO YOU PURSUANT TO THE OFFER IF THE TRANSFER AGENT DOES NOT HAVE A CORRECT, COMPLETED AND SIGNED VERSION OF THE APPROPRIATE IRS TAX FORM ON FILE.

What Number to Give the Transfer Agent

Each United States shareholder is generally required to give the Transfer Agent its social security number or employer identification number. If the tendering shareholder has not been issued a TIN and has applied for a

number or intends to apply for a number in the near future, the shareholder should write “Applied For” in Part I, sign and date the Form W-9. Notwithstanding that “Applied For” is written in Part I, the Transfer Agent will withhold 24% of all payments of the purchase price to such shareholder until a TIN is provided to the Transfer Agent. Such amounts will be refunded to such surrendering shareholder if a TIN is provided to the Transfer Agent within 60 days. Please consult your own accountant or tax advisor for further guidance regarding the completion of IRS Form W-9, IRS Form W-8BEN, IRS Form W-8BEN-E, or another version of IRS Form W-8 to claim exemption from backup withholding, or contact the Transfer Agent.

All authority herein conferred or agreed to be conferred shall survive the death or incapacity of the undersigned and the obligation of the undersigned hereunder shall be binding on the heirs, personal representatives, successors and assigns of the undersigned. Except as stated in Section 5 “Withdrawal Rights” of the Offer to Purchase, this tender is irrevocable.

Method of delivery of this Letter of Transmittal is at the option and risk of the owner thereof. If delivering via USPS, UPS or FedEx, please deliver this Letter of Transmittal in its entirety to the Transfer Agent:

SS&C GIDS, Inc.

Attention: Kennedy Lewis Capital Company

PO Box 219213

Kansas City, MO 64121-9213

A SHAREHOLDER CHOOSING TO EMAIL A LETTER OF TRANSMITTAL MUST ALSO MAIL THE ORIGINAL COMPLETED AND EXECUTED LETTER OF TRANSMITTAL (OR AN ORIGNALLY SIGNED PHOTCOPY THEREOF) PROMPTLY THEREAFTER.

If delivering an originally signed photocopy via email:

Email: kennedyai@dstsystems.com

If delivering via email, please include “Tender Offer for Kennedy Lewis Capital Company Common Shares” in the subject line.

DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE WILL NOT CONSTITUTE A VALID DELIVERY TO THE TRANSFER AGENT.

IF YOU WOULD LIKE ADDITIONAL COPIES OF THE OFFER TO PURCHASE, THIS LETTER OF TRANSMITTAL OR ANY OF THE OTHER DOCUMENTS RELATED TO THE OFFER TO PURCHASE, YOU SHOULD CONTACT THE TRANSFER AGENT TOLL-FREE AT (866) 966-0157 OR THE COMPANY BY EMAIL AT KENNEDYAI@DSTSYSTEMS.COM.

IT IS UNDERSTOOD THAT THE METHOD OF DELIVERY OF THIS LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS IS AT THE OPTION AND RISK OF THE UNDERSIGNED AND THAT THE RISK OF LOSS OF THIS LETTER OF TRANSMITTAL AND OTHER DOCUMENTS SHALL PASS ONLY AFTER THE TRANSFER AGENT HAS ACTUALLY RECEIVED THE LETTER OF TRANSMITTAL. IF DELIVERY IS BY MAIL, IT IS RECOMMENDED THAT ALL SUCH DOCUMENTS BE SENT BY PROPERLY INSURED REGISTERED MAIL WITH RETURN RECEIPT REQUESTED. IN ALL CASES, SUFFICIENT TIME SHOULD BE ALLOWED TO ENSURE TIMELY DELIVERY.

Questions and requests for assistance regarding the Offer may be directed to the Company by email at kennedyai@dstsystems.com.

Confirmation of receipt of this Letter of Transmittal may be directed to the Transfer Agent by phone at (866) 966-0157 or by regular mail at the following address: SS&C GIDS, Inc., Attention: Kennedy Lewis Capital Company, PO Box 219213, Kansas City, MO 64121-9213. The Company strongly recommends that you confirm receipt of your Letter of Transmittal with the Transfer Agent by calling (866) 966-0157, Monday through Friday, except holidays, during normal business hours of 9:00 a.m. to 6:00 p.m. (Eastern Time).

You may also contact your broker, dealer, commercial bank or trust company or other nominee for assistance concerning the Offer.

[Remainder of Page Intentionally Left Blank]

VALUATION DATE: December 31, 2023

 

TENDER OFFER EXPIRATION DATE: 11:59 p.m. (Eastern Time), December 29, 2023

 

PARTS 1, 2, 3, AND 4 MUST BE COMPLETED AND IN GOOD ORDER IN ORDER TO PROCESS YOUR

REQUEST

If You Invest In The Company Through A Financial Intermediary Through Whom You Expect To Have Your Tender Offer Request Submitted, Please Allow For Additional Processing Time As The Letter of Transmittal Must Ultimately Be Received By The Company’s Transfer Agent No Later Than 11:59 p.m. (Eastern Time) On The Expiration Date.

PLEASE SEND COMPLETED FORMS TO THE TRANSFER AGENT PURSUANT TO THE INSTRUCTIONS SET FORTH IN THE LETTER OF TRANSMITTAL.

PART 1. – NAME AND CONTACT INFORMATION (AS THEY APPEAR ON THE BOOKS AND RECORDS OF KENNEDY LEWIS CAPITAL COMPANY)

Name of Shareholder:

Company Account #:

Address:

City, State, Zip

Telephone Number:

Email Address:

Financial Intermediary Firm Name:

Financial Intermediary Account #:

Financial Advisor Name:

Financial Advisor Telephone #:

PART 2. – REQUESTED TENDER AMOUNT

Please select repurchase type by checking one of the boxes below. If you are requesting a partial repurchase, please provide a number of Common Shares.

☐	Full Repurchase
☐	Partial Repurchase* of      Common Shares (please only provide a number of Common Shares, not a dollar amount)
*	If the requested partial repurchase would put the account balance below the required minimum balance of $10,000, the Company reserves the right to repurchase all of your Common Shares.

PART 3. – PAYMENT

PAYMENT INSTRUCTIONS (Select only one)

Indicate how you wish to receive your payment for tendered and accepted Common Shares below. If an option is not selected, the proceeds for tendered and accepted Common Shares will be transmitted according to the wire instructions on record with the Transfer Agent (i.e., the same account to which cash dividends are paid, if any). Proceeds for qualified accounts, including IRAs and other custodial accounts, and certain broker-controlled accounts as required by your broker dealer of record, will automatically be issued to the custodian or broker dealer of record, as applicable. All custodial and broker-controlled accounts must include the custodian and/or broker dealer signature.

☐	Wire Transmittal to the Account on Record
☐	Cash/Check Mailed to Address of Record
☐	Cash/Check Mailed to Third Party/Custodian (Signature Guarantee required)

Name / Entity Name / Financial Institution		Mailing Address
City	State	Zip Code	Account Number

PART 4. – SIGNATURE(S)

(U.S. Holders — Please Also Complete IRS Form W-9 If the Transfer Agent Does Not Have a Correct, Completed and Signed Version on File)

(Non-U.S. Holders — Please Obtain and Complete IRS Form W-8BEN or W-8BEN-E (or Other Applicable IRS Form), as Appropriate, If the Transfer Agent Does Not Have a Correct, Completed and Signed Version of the Appropriate IRS Tax Form on File)

The undersigned Shareholder acknowledges that this request is subject to all the terms and conditions set forth in the Offer to Purchase and all capitalized terms used herein have the meaning as defined in the Offer to Purchase. This request is irrevocable except as described in the Offer to Purchase. The undersigned represents that the undersigned is the beneficial owner of the Common Shares to which this repurchase request relates, or that the person signing this request is an authorized representative of the tendering shareholder.

In the case of joint accounts, each joint holder must sign this repurchase request. Requests on behalf of a foundation, partnership or any other entity should be accompanied by evidence of the authority of the person(s) signing.

Signature	Print Name of Authorized Signatory (and Title if applicable)	Date
Signature	Print Name of Authorized Signatory (and Title if applicable)	Date

Must be signed by registered owner(s) exactly as name(s) appear(s) in the books and records of Kennedy Lewis Capital Company. If any Common Shares tendered hereby are owned of record by two or more joint owners, all such owners must sign this Letter of Transmittal. If any tendered Common Shares are registered in the names of different holder(s), it will be necessary to complete, sign and submit as many separate Letters of Transmittal as there are different registrations of such Common Shares. If this Letter of Transmittal or any certificates or stock powers are signed by trustees, executors, administrators, guardians, attorneys-in-fact, officers of corporations or others acting in a fiduciary or representative capacity, such persons should so indicate when signing, and proper evidence satisfactory to the Company of their authority so to act must be submitted.

Name:
	(Please Print)
Capacity (full title):
Address (include zip code):
Area Code and Telephone Number
Tax Identification or Social Security No.:

PAYOR’S NAME: KENNEDY LEWIS CAPITAL COMPANY

 

IMPORTANT: THIS LETTER OF TRANSMITTAL, TOGETHER WITH BOOK-ENTRY

CONFIRMATION AND ALL OTHER REQUIRED DOCUMENTS, MUST BE RECEIVED BY THE

TRANSFER AGENT ON OR PRIOR TO THE EXPIRATION DATE.

EX-99.(A)(1)(IV)

Exhibit (a)(1)(iv)

Form of Letter from the Company to Shareholders

in Connection with the Company’s Acceptance of Common Shares

KENNEDY LEWIS CAPITAL COMPANY

c/o SS&C GIDS, Inc.

PO Box 219213

Kansas City, MO 64121-9213

[     ], 2023

[SHAREHOLDER NAME/ADDRESS]

Dear Shareholder:

This letter serves to inform you that Kennedy Lewis Capital Company (the “Company”) has received and accepted for purchase your tender of common shares of beneficial interest, par value $0.01 (“Common Shares”), of the Company.

In accordance with the terms of the tender offer, the Company will effect payment for your tendered and accepted Common Shares in cash promptly after the determination of the net asset value per share as of December 31, 2023 (or a later date determined by the Company if the tender offer is extended) is finalized. The Company may use cash on hand, cash available from borrowings and cash from the liquidation of portfolio investments to fund the payment of your Common Shares.

If you have any questions, please contact SS&C GIDS, Inc., the Company’s transfer agent, at (866) 966-0157.

Sincerely,

Kennedy Lewis Capital Company

EX-99.(A)(1)(V)

Exhibit (a)(1)(v)

Notice of Withdrawal of Tender

Regarding Common Shares in Kennedy Lewis Capital Company

Tendered Pursuant to the Offer to Purchase

Dated November 30, 2023

The Offer and withdrawal rights will expire on December 29, 2023

and this Notice of Withdrawal must be received by

the Company’s Transfer Agent, either by mail or email, by 11:59 p.m.,

Eastern Time, on December 29, 2023, unless the Offer is extended

Complete this Notice of Withdrawal and follow the transmittal

instructions included herein

IMPORTANT: If you tendered your common shares of beneficial interest, par value $0.01 per share (the “Common Shares”), of Kennedy Lewis Capital (the “Company”) through your broker, dealer, commercial bank, trust company or other nominee, you must instruct the broker, dealer, commercial bank, trust company or other nominee to arrange for the withdrawal of your tendered Common Shares.

Complete this Notice of Withdrawal of Tender and return or deliver it to SS&C GIDS, Inc., Kennedy Lewis Capital Company’s transfer agent (the “Transfer Agent”), by mail or email as follows:

If delivering via USPS, UPS or FedEx:

SS&C GIDS, Inc.

Attention: Kennedy Lewis Capital Company

PO Box 219213

Kansas City, MO 64121-9213

A SHAREHOLDER CHOOSING TO EMAIL A NOTICE OF WITHDRAWAL OF TENDER MUST

ALSO MAIL THE ORIGINAL COMPLETED AND EXECUTED NOTICE OF WITHDRAWL OF

TENDER (OR AN ORIGNALLY SIGNED PHOTCOPY THEREOF) PROMPTLY THEREAFTER.

If delivering an originally signed photocopy via email:

Email: kennedyai@dstsystems.com

If delivering via email, please include “Tender Offer for Kennedy Lewis Capital Company Common Shares” in the subject line.

DELIVERY OF THIS NOTICE OF WITHDRAWAL OF TENDER TO AN ADDRESS OTHER

THAN AS SET FORTH ABOVE WILL NOT CONSTITUTE A VALID DELIVERY TO THE

TRANSFER AGENT.

For additional information, call the Transfer Agent at (866) 966-0157.

[Remainder of Page Intentionally Left Blank]

You are responsible for confirming that this Notice is received timely by the Transfer Agent. If you (or your broker, dealer, commercial bank, trust company or other nominee) fail to confirm receipt of this Notice, there can be no assurance that your withdrawal will be honored by the Company.

Ladies and Gentlemen:

Please withdraw the tender previously submitted by the undersigned in a Letter of Transmittal.

Name of Shareholder:

Company Account #:

Address:

City, State, Zip

Telephone Number:

Email Address:

Financial Intermediary Firm Name:

Financial Intermediary Account #:

Financial Advisor Name:

Financial Advisor Telephone #:

Such withdrawal is with respect to (specify one):

☐	All of the undersigned’s Common Shares previously tendered
☐	The following number of Common Shares previously tendered:

The undersigned recognizes that upon the submission on a timely basis of this Notice of Withdrawal of Tender, properly executed, the Common Shares previously tendered and indicated above will not be purchased by the Company upon expiration of the tender offer described above.

The undersigned represents that the undersigned is the beneficial owner of the common shares of beneficial interest, par value $0.01 per share, of the Company to which this withdrawal request relates, or that the person signing this request is an authorized representative of the withdrawing shareholder.

In the case of joint accounts, each joint holder must sign this withdrawal request. Requests on behalf of a foundation, partnership or any other entity should be accompanied by evidence of the authority of the person(s) signing.

Signature	Print Name of Authorized Signatory (and Title if applicable)	Date
Signature	Print Name of Authorized Signatory (and Title if applicable)	Date

Must be signed by registered owner(s) exactly as name(s) appear(s) in the books and records of Kennedy Lewis Capital Company. If any Common Shares covered by this Notice of Withdrawal are owned of record by two or more joint owners, all such owners must sign this Notice of Withdrawal. If any previously tendered Common Shares are registered in the names of different holder(s), it will be necessary to complete, sign and submit as many separate Notices of Withdrawal as there are different registrations of such Common Shares. If this Notice of Withdrawal or any certificates or stock powers are signed by trustees, executors, administrators, guardians, attorneys-in-fact, officers of corporations or others acting in a fiduciary or representative capacity, such persons should so indicate when signing, and proper evidence satisfactory to the Company of their authority so to act must be submitted.

Name:
	(Please Print)

Capacity (full title):

Address (include zip code):

Area Code and Telephone Number

Tax Identification or Social Security No.:

EX-FILING FEES

EX-FILING FEES

Calculation of Filing Fee Tables

Schedule TO

(Form Type)

Kennedy Lewis Capital Company

(Exact Name of Registrant as Specified in its Charter)

Table 1: Transaction Valuation

	Transaction Valuation	Fee Rate			Amount of Filing Fee
Fees to Be Paid	$                     11,011,772.85(1)		0.0001476	$	1,625.34(2)
Fees Previously Paid
Total Transaction Valuation	$                     11,011,772.85(1)			$	1,625.34(2)
Total Fees Due for Filing
Total Fees Previously Paid						—
Total Fee Offsets						—
Net Fee Due				$		1,625.34

(1) Calculated solely for purposes of determining the amount of the filing fee. This amount is based upon the offer to purchase up to 538,473 common shares of beneficial interest, par value $0.01 per share, of Kennedy Lewis Capital Company (the “Company”), at a price equal to $20.45, which represents the Company’s net asset value as of October 31, 2023, and is used for purposes of calculating the estimated aggregate maximum purchase price for shares.

(2) The amount of the filing fee, calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, as modified by Fee Rate Advisory No. 1 for fiscal year 2024, equals $147.60 per million dollars of the value of the transaction.